Your browser doesn't support javascript.
loading
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Ang, Joo Ern; Pandher, Rupinder; Ang, Joo Chew; Asad, Yasmin J; Henley, Alan T; Valenti, Melanie; Box, Gary; de Haven Brandon, Alexis; Baird, Richard D; Friedman, Lori; Derynck, Mika; Vanhaesebroeck, Bart; Eccles, Suzanne A; Kaye, Stan B; Workman, Paul; de Bono, Johann S; Raynaud, Florence I.
Afiliação
  • Ang JE; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Pandher R; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Ang JC; School of Physics, University of Melbourne, Melbourne, Victoria, Australia.
  • Asad YJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Henley AT; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Valenti M; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Box G; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • de Haven Brandon A; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Baird RD; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Friedman L; Genentech Inc., South San Francisco, California.
  • Derynck M; Genentech Inc., South San Francisco, California.
  • Vanhaesebroeck B; UCL Cancer Institute, University College London, London, United Kingdom.
  • Eccles SA; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Kaye SB; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Workman P; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • de Bono JS; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
  • Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom. Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. Florence.Raynaud@icr.ac.uk.
Mol Cancer Ther ; 15(6): 1412-24, 2016 06.
Article em En | MEDLINE | ID: mdl-27048952
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Biomarcadores Tumorais / PTEN Fosfo-Hidrolase / Metaboloma / Indazóis / Neoplasias Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulfonamidas / Biomarcadores Tumorais / PTEN Fosfo-Hidrolase / Metaboloma / Indazóis / Neoplasias Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Assunto da revista: ANTINEOPLASICOS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido